Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic DOI Creative Commons
Iqra Mir, Sania Aamir, Syed Rizwan Hussain Shah

и другие.

Osong Public Health and Research Perspectives, Год журнала: 2022, Номер 13(2), С. 84 - 100

Опубликована: Апрель 27, 2022

The coronavirus disease 2019 (COVID-19) pandemic rapidly spread globally. Severe acute respiratory syndrome 2 (SARS-CoV-2), which causes COVID-19, is a positive-sense single-stranded RNA virus with reported fatality rate ranging from 1% to 7%, and people immune-compromised conditions, children, older adults are particularly vulnerable. Respiratory failure cytokine storm-induced multiple organ the major of death. This article highlights innate adaptive immune mechanisms host cells activated in response SARS-CoV-2 infection possible therapeutic approaches against COVID-19. Some potential drugs proven be effective for other viral diseases under clinical trials now use Examples include inhibitors RNA-dependent polymerase (remdesivir, favipiravir, ribavirin), protein synthesis (ivermectin, lopinavir/ritonavir), fusion membrane (chloroquine, hydroxychloroquine, nitazoxanide, umifenovir). also presents intellectual groundwork ongoing development vaccines preclinical trials, explaining candidates (live attenuated-whole vaccines, inactivated subunit DNA-based protein-based nanoparticle-based virus-like particles mRNA-based vaccines). Designing developing an vaccine (both prophylactic therapeutic) would long-term solution most way eliminate COVID-19 pandemic.

Язык: Английский

Pharmacokinetic Interaction Between Favipiravir and Amlodipine in Hypertensive Local Rabbits (Oryctolagus cuniculus) DOI Creative Commons

Ali I. Al-ameedi,

Falah Muosa Kadhim Al-Rekabi

The Iraqi Journal of Veterinary Medicine, Год журнала: 2023, Номер 47(1), С. 38 - 43

Опубликована: Июнь 28, 2023

In the treatment of COVID-19, antiviral medication Favipiravir has proven to be quite successful. Its metabolism is mediated by enzymes aldehyde oxidase (AO) and xanthine (XO). This research investigated potential drug-drug interaction betweenfavipiravir amlodipine in hypertensive rabbits. Twenty local adult male rabbits (aged between 10 12 months weighing 2 2.5 kg) were induced with hypertension 20 mg/kg BW desoxycorticosterone acetate subcutaneously for three weeks then divided randomly into two groups ten. The first group received a single oral dose 40 favipiravir, while second 5 orally 14 consecutive days inhibit AO before receiving favipiravir. Blood samples collected from marginal ear vein at 15, 30, 45 min, 1, 2, 4, 8, 12, 24, 48, 36, 72 h. High-performance liquid chromatography (HPLC) was used determine concentration favipiravir plasma. results showed that co-administration prolonged time taken (Tmax) reach maximum plasma (Cmax) decreased its elimination half-life, increasing area under curve (AUC). Amlodipine also reducing clearance per unit (Cl/f). Additionally, potentiated effect on absorption, distribution, metabolism, excretion conclusion, concomitant use other drugs affect enzyme activity may alter pharmacokinetic profile drug. Therefore, adjusting administered patients recommended.

Язык: Английский

Процитировано

1

Divergences in Antiviral Therapy for Diabetic Patients with COVID-19 DOI Open Access
Andreea Fitero, Nicoleta Negruț, Carmen Delia Nistor-Cseppento

и другие.

Опубликована: Фев. 7, 2024

Abstract: Background: Patients with diabetes are particularly susceptible to COVID-19 infection, which can result in severe respiratory illness. Methods: This study conducted a comparative as-sessment of the impact antiviral therapy using molnupiravir and favipiravir pa-tients underlying diabetes. A cohort one hundred individuals infected SARS-CoV-2, diagnosed diabetes, consecutively admitted, was included present study. These patients were treated antivirals according local guidelines: Group F (51 cases) – 10 days M (49 5 days. Re-sults: In F, average hospitalization higher than (11.29±2.27 vs. 7.14±3.16, p

Язык: Английский

Процитировано

0

Sub-acute toxicity of the standardised extract of Boesenbergia rotunda in rats DOI Open Access

Pinnakarn Techapichetvanich,

Phisit Khemawoot,

Passaraporn Srimangkornkaew

и другие.

ScienceAsia, Год журнала: 2024, Номер 50(3), С. 1 - 1

Опубликована: Янв. 1, 2024

An in vitro study of Thai medicinal plants revealed anti-SARS-CoV-2 activity ethanolic extract Boesenbergia rotunda and its bioactive component panduratin A. The present aims to evaluate the safety after 28 consecutive days oral doses according OECD GLP 407.The 28-day repeated were performed both male female Wistar rats.Three 150, 300 600 mg/kg/day assigned as low, medium high doses, respectively.During administration period, there was no evidence morbidity, mortality, or neurological toxicity for gender all doses.Weight food water intake similar control group.The hematological clinical biochemistry parameters within normal ranges rats.The oestrous cycle animals groups vaginal cytology investigation showed abnormal cellular types.The statistically significant difference weight organs no-test itemrelated effects histopathological examination remarkable lesion.The observed adverse effect level (NOAEL) B. considered be mg/kg body per day.These findings are useful information developing a potential phytopharmaceutical product future investigation.

Язык: Английский

Процитировано

0

EFFECTS OF ANTIVIRAL THERAPEUTIC DRUGS FOR SARS-COV-2 ON TREATMENT OUTCOMES AND CLINICAL PARAMETERS DOI Open Access

Abdul Bari,

Atiqullah Sarwari,

Mohammad Hassan

и другие.

Eurasian Journal of Ecology, Год журнала: 2024, Номер 79(2), С. 136 - 146

Опубликована: Янв. 1, 2024

The emergence of SARS-CoV-2, the virus responsible for COVID-19 pandemic, has prompted extensive research into antiviral therapeutic interventions aimed at improving treatment outcomes and clinical parameters. It provides a concise overview conducted in this field, focusing on impact significance various drugs. By analyzing key studies trials, it aims to elucidate efficacy safety profiles drugs such as remdesivir, favipiravir, molnupiravir, Paxlovid managing COVID-19. scientific practical lies its contribution understanding role combating SARS-CoV-2 infection. This knowledge is crucial optimizing strategies patient during ongoing pandemic. Methodologically, involves reviewing synthesizing data from reputable published peer-reviewed journals. Key parameters assessed include viral clearance, mortality rates, hospitalization duration, adverse effects associated with drug administration. main results analysis highlight varying impacts different outcomes. For instance, remdesivir shows promise reducing recovery time mortality, while favipiravir demonstrates enhanced clearance but may cause transient liver enzyme elevations. In conclusion, underscores value mitigating findings contribute evolving offer insights care protocols. these informing healthcare professionals policymakers about effective options cases, ultimately abstract encapsulates essential aspects emphasizing scientific, practical, methodological advancing our response global

Язык: Английский

Процитировано

0

Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic DOI Creative Commons
Iqra Mir, Sania Aamir, Syed Rizwan Hussain Shah

и другие.

Osong Public Health and Research Perspectives, Год журнала: 2022, Номер 13(2), С. 84 - 100

Опубликована: Апрель 27, 2022

The coronavirus disease 2019 (COVID-19) pandemic rapidly spread globally. Severe acute respiratory syndrome 2 (SARS-CoV-2), which causes COVID-19, is a positive-sense single-stranded RNA virus with reported fatality rate ranging from 1% to 7%, and people immune-compromised conditions, children, older adults are particularly vulnerable. Respiratory failure cytokine storm-induced multiple organ the major of death. This article highlights innate adaptive immune mechanisms host cells activated in response SARS-CoV-2 infection possible therapeutic approaches against COVID-19. Some potential drugs proven be effective for other viral diseases under clinical trials now use Examples include inhibitors RNA-dependent polymerase (remdesivir, favipiravir, ribavirin), protein synthesis (ivermectin, lopinavir/ritonavir), fusion membrane (chloroquine, hydroxychloroquine, nitazoxanide, umifenovir). also presents intellectual groundwork ongoing development vaccines preclinical trials, explaining candidates (live attenuated-whole vaccines, inactivated subunit DNA-based protein-based nanoparticle-based virus-like particles mRNA-based vaccines). Designing developing an vaccine (both prophylactic therapeutic) would long-term solution most way eliminate COVID-19 pandemic.

Язык: Английский

Процитировано

1